Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 13/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.74 |
| ▸ | GSK3B | P49841 | 4/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4053992 | 0.80 | ADORA2A (0.70) | ADORA2BADORA2AADORA1ADORA3GSK3B | |
| SCHEMBL3791797 | 0.78 | ADORA2B (0.64) | ADORA2BADORA2AADORA1ADORA3GSK3B | |
| SCHEMBL6765797 | 0.76 | CDC7 (0.55) | ADORA2BADORA2AADORA1ADORA3GSK3B | |
| SCHEMBL4049728 | 0.75 | ADORA2A (0.52) | ADORA2BADORA2AADORA1ADORA3CYP3A4 | |
| SCHEMBL4059867 | 0.74 | ADORA2A (0.51) | ADORA2BADORA2AADORA1ADORA3CYP3A4 | |
| SCHEMBL5461691 | 0.73 | ADORA1 (0.69) | ADORA2BADORA2AADORA1ADORA3NPY5R | |
| SCHEMBL4052370 | 0.72 | ADORA2A (0.47) | ADORA2BADORA2AADORA1ADORA3CYP3A4 | |
| SCHEMBL5456365 | 0.72 | ADORA1 (0.56) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL4333014 | 0.71 | GSK3B (0.65) | ADORA2BADORA2AADORA1ADORA3GSK3B | |
| SCHEMBL4052641 | 0.71 | ADORA2A (0.48) | ADORA2BADORA2AADORA1ADORA3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-22 | — | — | US | disclosed |
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-22 | — | — | US | disclosed |
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023763-A1 | Condensed Pyridine Derivatives Useful as A2B Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.